In summary, the evidence suggests that ECS and ketamine share common neuroplastic mechanisms—particularly involving hippocampal neurogenesis, BDNF upregulation, and enhanced glutamatergic function—which may underlie their rapid antidepressant effects and provide a basis for future treatment strategies for patients with severe depression [71]. The gene discussed is BDNF; the disease is depressive symptom measurement.